Chitosan-DNA nanoparticles delivered by intrabiliary infusion enhance liver-targeted gene delivery

International Journal of Nanomedicine

Volumn 1, Issue 4, 2006, Pages 507-522

  Dai, Hui ^a,b,d   Jiang, Xuan ^e   Tan, Geoffrey C Y ^a,f   Chen, Yong ^b   Torbenson, Michael ^c   Leong, Kam W ^a,d   Mao, Hai Quan ^a,e  

^a Johns Hopkins Singapore   (Singapore)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Duke University   (United States)

^e Johns Hopkins University   (United States)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Chitosan; Gene delivery; Liver targeted; Nanoparticles; Retrograde intrabiliary infusion

Indexed keywords

CHITOSAN; DNA; DRUG CARRIER; NANOPARTICLE;

ANIMAL; ARTICLE; BILE DUCT; CHEMISTRY; EVALUATION; GENE TARGETING; GENETIC TRANSFECTION; INFUSION; LIVER; MALE; METABOLISM; METHODOLOGY; PARTICLE SIZE; RAT; ULTRASTRUCTURE; WISTAR RAT;

ANIMALS; BILE DUCTS; CHITOSAN; DNA; DRUG CARRIERS; GENE TARGETING; INFUSIONS, PARENTERAL; LIVER; MALE; NANOPARTICLES; PARTICLE SIZE; RATS; RATS, WISTAR; TRANSFECTION;

EID: 34447257278     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/nano.2006.1.4.507     Document Type: Article

References (63)

1. Asad SF, Singh S, Ahmad A, et al. 1999. Bilirubin-Cu(II) complex degrades DNA. Biochim Biophys Acta, 1428:201-8.
2. Asad SF, Singh S, Ahmad A, et al. 2002. Bilirubin/biliverdin-Cu(II) induced DNA breakage; reaction mechanism and biological significance. Toxicol Lett, 131:181-9.
3. Borchard G. 2001. Chitosans for gene delivery. Adv Drug Deliv Rev, 52:145-50.
4. Bowman K, Sarkar R, Wang XL, et al. 2004. Evaluation of non-viral vectors for gene therapy of hemophilia A. Mol Ther, 9:S314.
5. Cheah PY, Bernstein H. 1990. Modification of DNA by bile acids: a possible factor in the etiology of colon cancer. Cancer Lett, 49:207-210.
6. Chellat F, Grandjean-Laquerriere A, Le Naour R, et al. 2005. Metallo-proteinase and cytokine production by THP-1 macrophages following exposure to chitosan-DNA nanoparticles. Biomaterials, 26:961-70.
7. Chen CY, Liu HS, Lin XZ. 2005. Hydrodynamics-based gene delivery to the liver by bile duct injection of plasmid DNA-the impact of lasting biliary obstruction and injection volume. Hepatogastroenterology, 52:25-8.
8. Cheung ST, Tsui TY, Wang WL, et al. 2002. Liver as an ideal target for gene therapy: expression of CTLA4Ig by retroviral gene transfer. J Gastroenterol Hepatol, 17:1008-14.
9. Chew JL, Wolfowicz CB, Mao HQ, et al. 2003. Chitosan nanoparticles containing plasmid DNA encoding house dust mite allergen, Der p 1 for oral vaccination in mice. Vaccine, 21:2720-9.
10. Chia SM, Leong KW, Li J, et al. 2000. Hepatocyte encapsulation for enhanced cellular functions. Tissue Eng, 6:481-95.
11. Chou TC, Fu E, Shen EC. 2003. Chitosan inhibits prostaglandin E2 formation and cyclooxygenase-2 induction in lipopolysaccharide-treated RAW 264.7 macrophages. Biochem Biophys Res Commun, 308:403-7.
12. Cichon G, Schmidt HH, Benhidjeb T, et al. 1999. Intravenous administration of recombinant adenoviruses causes thrombocytopenia, anemia and erythroblastosis in rabbits. J Gene Med, 1:360-71.
13. Coleman R, Rahman K, Kan KS, et al. 1989. Retrograde intrabiliary injection of amphipathic materials causes phospholipid secretion into bile. Taurocholate causes phosphatidylcholine secretion, 3-[(3-cholamidopropyl)dimethylammonio]-propane-1-sulphonate (CHAPS) causes mixed phospholipid secretion. Biochem J, 258:17-22.
14. Cristiano RJ, Smith LC, Kay MA, et al. 1993. Hepatic gene therapy: efficient gene delivery and expression in primary hepatocytes utilizing a conjugated adenovirus-DNA complex. Proc Natl Acad Sci U S A, 90:11548-52.
15. De Godoy JL, Malafosse R, Fabre M, et al. 1999. In vivo hepatocyte retrovirus-mediated gene transfer through the rat biliary tract. Hum Gene Ther, 10:249-57.
16. Higuchi N, Maruyama H, Kuroda T, et al. 2003. Hydrodynamics-based delivery of the viral interleukin-10 gene suppresses experimental crescentic glomerulonephritis in Wistar-Kyoto rats. Gene Ther, 10:1297-310.
17. Jooss K, Chirmule N. 2003. Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy. Gene Ther, 10:955-63.
18. Kawakami S, Yamashita F, Nishida K, et al. 2002. Glycosylated cationic liposomes for cell-selective gene delivery. Crit Rev Ther Drug Carrier Syst, 19:171-90.
19. Kim MS, You HJ, You MK, et al. 2004. Inhibitory effect of water-soluble chitosan on TNF-alpha and IL-8 secretion from HMC-1 cells. Immunopharmacol Immunotoxicol, 26:401-9.
20. Koping-Hoggard M, Tubulekas I, Guan H, et al. 2001. Chitosan as a nonviral gene delivery system. Structure-property relationships and characteristics compared with polyethylenimine in vitro and after lung administration in vivo. Gene Ther, 8:1108-21.
21. Kren BT, Chowdhury NR, Chowdhury JR, et al. 2002. Gene therapy as an alternative to liver transplantation. Liver Transpl, 8:1089-1108.
22. Kuhel DG, Zheng S, Tso P, et al. 2000. Adenovirus-mediated human pan-creatic lipase gene transfer to rat bile: gene therapy of fat malabsorption. Am J Physiol Gastrointest Liver Physiol, 279:G1031-6.
23. Lecocq M, Andrianaivo F, Warnier MT, et al. 2003. Uptake by mouse liver and intracellular fate of plasmid DNA after a rapid tail vein injection of a small or a large volume. J Gene Med, 5:142-56.
24. Leong KW, Mao HQ, Truong L, et al. 1998. DNA-polycation nanospheres as non-viral gene delivery vehicles. J Control Release, 53:183-93.
25. Li S, Huang L. 1997. In vivo gene transfer via intravenous administration of cationic lipid-protamine-DNA (LPD) complexes. Gene Ther, 4:891-900.
26. Liu F, Song Y, Liu D. 1999. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther, 6:1258-66.
27. Liu WG, Yao KD. 2002. Chitosan and its derivatives--a promising non-viral vector for gene transfection. J Control Release, 83:1-11.
28. Ludwig J, Ritman EL, LaRusso NF, et al. 1998. Anatomy of the human biliary system studied by quantitative computer-aided three-dimensional imaging techniques. Hepatology, 27:893-9.
29. MacLaughlin FC, Mumper RJ, Wang J, et al. 1998. Chitosan and depolymerized chitosan oligomers as condensing carriers for in vivo plasmid delivery. J Control Release, 56:259-72.
30. Mahato RI, Kawabata K, Takakura Y, et al. 1995. In vivo disposition characteristics of plasmid DNA complexed with cationic liposomes. J Drug Target, 3:149-57.
31. Mao HQ, Roy K, Troung L, et al. 2001. Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. J Control Release, 70:399-421.
32. Masamune K, Kunitomo K, Sasaki K, et al. 1997. Bile-induced DNA strand breaks and biochemical analysis of bile acids in an experimental model of anomalous arrangement of the pancreaticobiliary ducts. J Med Invest, 44:47-51.
33. Murakami T, Sato H, Nakatani S, et al. 2001. Biliary tract of the rat as observed by scanning electron microscopy of cast samples. Arch Histol Cytol, 64:439-47.
34. Nathwani AC, Davidoff AM, Hanawa H, et al. 2002. Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques. Blood, 100:1662-9.
35. Nguyen TH, Ferry N. 2004. Liver gene therapy: advances and hurdles. Gene Ther, 11(Suppl 1):S76-84.
36. Niidome T, Huang L. 2002. Gene therapy progress and prospects: nonviral vectors. Gene Ther, 9:1647-52.
37. Okamoto H, Nishida S, Todo H, et al. 2003. Pulmonary gene delivery by chitosan-pDNA complex powder prepared by a supercritical carbon dioxide process. J Pharm Sci, 92:371-80.
38. Otsuka M, Baru M, Delriviere L, et al. 2000. In vivo liver-directed gene transfer in rats and pigs with large anionic multilamellar liposomes: routes of administration and effects of surgical manipulations on transfection efficiency. J Drug Target, 8:267-79.
39. Polimeno L, Azzarone A, Zeng QH, et al. 1995. Cell proliferation and oncogene expression after bile duct ligation in the rat: evidence of a specific growth effect on bile duct cells. Hepatology, 21:1070-8.
40. Prego C, Garcia M, Torres D, et al. 2005. Transmucosal macromolecular drug delivery. J Control Release, 101:151-62.
41. Prieto J, Herraiz M, Sangro B, et al. 2003. The promise of gene therapy in gastrointestinal and liver diseases. Gut, 52:ii49-54.
42. Rogers JV, Bigley NJ, Chiou HC, et al. 2000. Targeted delivery of DNA encoding herpes simplex virus type-1 glycoprotein D enhances the cellular response to primary viral challenge. Arch Dermatol Res, 292:542-9.
43. Roy K, Mao HQ, Huang SK, et al. 1999. Oral gene delivery with chitosan--DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med, 5:387-91.
44. Saxena R, Zucker SD, Crawford JM. 2003. Anatomy and physiology of the liver. In Zakim D, Boyer TD (eds). Hepatology, a textbook of liver disease. 4th ed. Philadelphia: Saunders. p 3-30.
45. Schipper NG, Olsson S, Hoogstraate JA, et al. 1997. Chitosans as absorption enhancers for poorly absorbable drugs 2: mechanism of absorption enhancement. Pharm Res, 14:923-9.
46. Seo SB, Jeong HJ, Chung HS, et al. 2003. Inhibitory effect of high molecular weight water-soluble chitosan on hypoxia-induced inflammatory cytokine production. Biol Pharm Bull, 26:717-21.
47. Sullivan DE, Dash S, Du H, et al. 1997. Liver-directed gene transfer in non-human primates. Hum Gene Ther, 8:1195-206.
48. Tang Y, Shah K, Messerli SM, et al. 2003. In vivo tracking of neural progenitor cell migration to glioblastomas. Hum Gene Ther, 14:1247-54.
49. Terao R, Honda K, Hatano E, et al. 1998. Suppression of proliferative cholangitis in a rat model with direct adenovirus-mediated retino-blastoma gene transfer to the biliary tract. Hepatology, 28:605-12.
50. Tominaga K, Kuriyama S, Yoshiji H, et al. 2004. Repeated adenoviral administration into the biliary tract can induce repeated expression of the original gene construct in rat livers without immunosuppressive strategies. Gut, 53:1167-73.
51. Treco DA, Selden RF. 1995. Non-viral gene therapy. Mol Med Today, 1:314-21.
52. Uehara T, Honda K, Hatano E, et al. 1999. Gene transfer to the rat biliary tract with the HVJ-cationic liposome method. J Hepatol, 30:836-42.
53. van der Merwe SM, Verhoef JC, Verheijden JH, et al. 2004. Trimethylated chitosan as polymeric absorption enhancer for improved peroral delivery of peptide drugs. Eur J Pharm Biopharm, 58:225-35.
54. Vroman B, LaRusso NF. 1996. Development and characterization of polarized primary cultures of rat intrahepatic bile duct epithelial cells. Lab Invest, 74:303-13.
55. Wang J, Gao SJ, Zhang PC, et al. 2004. Polyphosphoramidate gene carriers: effect of charge group on gene transfer efficiency. Gene Ther, 11:1001-10.
56. Wu J, Nantz MH, Zern MA. 2002. Targeting hepatocytes for drug and gene delivery: emerging novel approaches and applications. Front Biosci, 7:717-25.
57. Yang Y, Raper SE, Cohn JA, et al. 1993. An approach for treating the hepatobiliary disease of cystic fibrosis by somatic gene transfer. Proc Natl Acad Sci U S A, 90:4601-5.
58. Yoo SH, Lee JS, Park SY, et al. 2005. Effects of selective oxidation of chitosan on physical and biological properties. Int J Biol Macromol, 35:27-31.
59. Zhang G, Budker V, Wolff JA. 1999. High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum Gene Ther, 10:1735-7.
60. Zhang G, Vargo D, Budker V, et al. 1997. Expression of naked plasmid DNA injected into the afferent and efferent vessels of rodent and dog livers. Hum Gene Ther, 8:1763-72.
61. Zhang W, Yang H, Kong X, et al. 2005. Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene. Nat Med, 11:56-62.
62. Zhang X, Collins L, Sawyer GJ, et al. 2001. In vivo gene delivery via portal vein and bile duct to individual lobes of the rat liver using a polylysine-based nonviral DNA vector in combination with chloroquine. Hum Gene Ther, 12:2179-90.
63. Zhang X, Sawyer GJ, Dong X, et al. 2003. The in vivo use of chloroquine to promote non-viral gene delivery to the liver via the portal vein and bile duct. J Gene Med, 5:209-18.